Results 11 to 20 of about 384,012 (260)

Exercise limitations in amyloid cardiomyopathy assessed by cardiopulmonary exercise testing—A multicentre study

ESC Heart Failure
Aims Amyloid cardiomyopathy is caused by the deposition of light chain (AL) or transthyretin amyloid (ATTR) fibrils, that leads to a restrictive cardiomyopathy, often resulting in heart failure (HF) with preserved or reduced ejection fraction. This study
Robin Willixhofer, Mauro Contini, Michele Emdin, Damiano Magrì, Alice Bonomi, Elisabetta Salvioni, Fabrizio Celeste, Alberico Del Torto, Claudio Passino, Christophe D.J. Capelle, Chiara Arzilli, Emiliano Fiori, Nicolò Capra, Christina Kronberger, Nikita Ermolaev, Andreas Kammerlander, Beatrice Musumeci, Giuseppe Vergaro, Vincenzo Castiglione, René Rettl, Giacomo Tini, Andrea Baggiano, Iacopo Fabiani, Susanna Sciomer, Roza Badr Eslam, Piergiuseppe Agostoni   +25 more
doaj   +3 more sources

Prevalence and characteristics of transthyretin amyloid cardiomyopathy in hypertrophic cardiomyopathy

ESC Heart Failure
Aims Recognition of transthyretin amyloid cardiomyopathy is increasing due to advances in cardiac imaging and diagnostic strategies, but questions remain regarding disease frequency and characteristics.
Pablo Garcia‐Pavia, Thibaud Damy, Nicolas Piriou, Roberto Barriales‐Villa, Francesco Cappelli, Catherine Bahus, Carmen Munteanu, Denis Keohane, Pablo Mallaina, Perry Elliott, the TTRACK investigators   +10 more
doaj   +2 more sources

Cardiac Biomarker Change at 1 Year After Tafamidis Treatment and Clinical Outcomes in Patients With Transthyretin Amyloid Cardiomyopathy

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Although tafamidis treatment improves prognosis in patients with wild‐type transthyretin amyloid cardiomyopathy, an optimal surrogate marker monitoring its therapeutic effect remains unclear.
Naoto Kuyama, Seiji Takashio, Tetsuya Oguni, Masahiro Yamamoto, Kyoko Hirakawa, Masanobu Ishii, Shinsuke Hanatani, Seitaro Oda, Yasushi Matsuzawa, Hiroki Usuku, Eiichiro Yamamoto, Toshinori Hirai, Mitsuharu Ueda, Kenichi Tsujita   +13 more
doaj   +2 more sources

Transthyretin amyloid cardiomyopathy: from cause to novel treatments. [PDF]

Eur Heart J
Graphical Abstract Graphical Abstract Imbalance between amyloid deposition and clearance as the driver of transthyretin amyloidosis onset and progression: perspectives for treatment. Abs, antibodies; nex-z, nexiguran ziclumeran; TTR, transthyretin.
Fontana M, Aimo A, Emdin M, Porcari A, Solomon SD, Hawkins PN, Gillmore JD.   +6 more
europepmc   +2 more sources

Correlation Between Cardiac Images, Biomarkers, and Amyloid Load in Wild‐Type Transthyretin Amyloid Cardiomyopathy

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2022
Background Several imaging parameters and biomarkers provide diagnostic and prognostic information for wild‐type transthyretin amyloid cardiomyopathy.
Mami Morioka, Seiji Takashio, Naoya Nakashima, Masato Nishi, Akira Fujiyama, Kyoko Hirakawa, Shinsuke Hanatani, Hiroki Usuku, Eiichiro Yamamoto, Masafumi Kidoh, Seitaro Oda, Kenichi Matsushita, Mitsuharu Ueda, Kenichi Tsujita   +13 more
doaj   +1 more source

A machine learning model for identifying patients at risk for wild-type transthyretin amyloid cardiomyopathy

Nature Communications, 2021
Transthyretin amyloid cardiomyopathy is a treatable but often unrecognized cause of heart failure. We derived and validated a machine learning model based on medical diagnostic codes that identifies heart failure patients at risk for wild-type ...
Ahsan Huda, Adam Castaño, Anindita Niyogi, Jennifer Schumacher, Michelle Stewart, Marianna Bruno, Mo Hu, Faraz S. Ahmad, Rahul C. Deo, Sanjiv J. Shah   +9 more
doaj   +1 more source

Beta-Adrenergic Antagonist Tolerance in Amyloid Cardiomyopathy

Frontiers in Cardiovascular Medicine, 2022
Background:Beta-adrenergic antagonists or blockers (BB) are a cornerstone of cardiac therapy for multiple indications. However, BB are considered relatively contraindicated in amyloid cardiomyopathy due to poor tolerance. This intolerance is hypothesized
Stuart Ramsell, Carlos Arias Bermudez, Cyril Ayuk Mbeng Takem Baiyee, Brandon Rodgers, Samir Parikh, Salem Almaani, Nidhi Sharma, Samantha LoRusso, Miriam Freimer, Elyse Redder, Naresh Bumma, Ajay Vallkati, Yvonne Efebera, Rami Kahwash, Courtney M. Campbell, Courtney M. Campbell   +15 more
doaj   +1 more source

Advanced isolated light chain amyloid cardiomyopathy with negative immunofixation and normal free light chain ratio

ESC Heart Failure, 2021
Amyloid light chain (AL) cardiomyopathy is the most malignant specific cardiomyopathy. According to international recommendations, it should be ruled out non‐invasively using the serum free light chain (FLC) ratio and immunofixation electrophoresis in ...
David Zach, Klemens Ablasser, Ewald Kolesnik, Viktoria Hoeller, Friedrich Fruhwald, Florian Prüller, Clemens Reiter, Christine Beham‐Schmid, Rainer Lipp, Peter P. Rainer, Andreas Zirlik, Albert Wölfler, Nicolas Verheyen   +12 more
doaj   +1 more source

Generation of an induced pluripotent stem cell line (ESi107-A) from a transthyretin amyloid cardiomyopathy (ATTR-CM) patient carrying a p.Ser43Asn mutation in the TTR gene

Stem Cell Research, 2023
Transthyretin (TTR) amyloid cardiomyopathy (ATTR-CM) is a life-threatening disease caused by the abnormal production of misfolded TTR protein by liver cells, which is then released systemically.
Pilar Montero-Calle, María Flandes-Iparraguirre, Bernd Kuebler, Begoña Arán, Eduardo Larequi, Ilazki Anaut, Giulia Coppiello, Xabier L. Aranguren, Anna Veiga, Maria Teresa Basurte Elorz, Manuel García de Yébenes, Juan J. Gavira, Felipe Prósper, Olalla Iglesias-García, Manuel M. Mazo Vega   +14 more
doaj   +1 more source

Transthyretin amyloid cardiomyopathy: natural history and treatment response assessed by cardiovascular magnetic resonance. [PDF]

Eur Heart J
Background and Aims Cardiovascular magnetic resonance (CMR) and extracellular volume (ECV) mapping can measure amyloid burden in vivo. This study sought to assess the natural history of transthyretin amyloid cardiomyopathy (ATTR-CM) in terms of amyloid ...
Patel RK, Ioannou A, Sheikh A, Razvi Y, Mansell J, Martinez-Naharro A, Knight D, Kotecha T, Porcari A, Chacko L, Brown J, Manisty C, Moon JC, Lachmann HJ, Wechalekar A, Whelan C, Venneri L, Kellman P, Hawkins PN, Gillmore JD, Fontana M.   +20 more
europepmc   +2 more sources